Antigen skin test sales will strengthen through 2036, anchored by bacterial infections at 40.0% of the test type segment in 2026, driven by standardized treatment protocols and established clinical procurement patterns. The market is projected to reach USD 2.6 billion in 2026 and USD 4.34 billion by 2036.